newsfilter
← Latest News
GlobeNewswire·

Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering

COAG
  • Hemab Therapeutics Holdings, Inc. priced its initial public offering of 16,750,000 shares at $18.00 per share.
  • The company granted underwriters a 30-day option to purchase up to an additional 2,512,500 shares.
  • All shares in the offering are being sold by Hemab Therapeutics.
  • Common stock is expected to begin trading on the Nasdaq Global Select Market on Friday, May 1, 2026, under the ticker symbol "COAG".
  • Gross proceeds from the offering are expected to be approximately $301.5 million, excluding the underwriters' option.
  • The offering is expected to close on or about May 4, 2026, subject to customary closing conditions.
  • Goldman Sachs & Co. LLC, Jefferies, and Evercore ISI are acting as joint book-running managers.
  • Wedbush PacGrow is acting as the lead manager for the offering.
  • The registration statement with the Securities and Exchange Commission was declared effective on April 30, 2026.
  • Hemab is a clinical-stage biotechnology company developing therapies for blood coagulation disorders, including sutacimig (HMB-001) and HMB-002.